close
Add to watchlist
Orexigen Therapeutics Inc (OREX)
Orexigen Therapeutics, Inc., a biopharmaceutical company, focusing on the development of pharmaceutical product candidates for the treatment of obesity. The company's lead combination product candidates targeted for obesity are Contrave, which is in Phase III clinical trials, and Empatic, which is in the later stages of Phase II clinical development. It selected these two product candidates for obesity based research regarding CNS regulation of appetite and energy expenditure, as well as mechanisms in the brain that reinforce unhealthy eating behaviors. Each of these product candidates is a combination of generic drugs that is screened for synergistic CNS activity. Orexigen Therapeutics was founded in 2002 and is headquartered in La Jolla, California.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 4.54 |
| Volume | (mio) 1.9 |
| Volume Avg | (mio) 1.4 |
| 52 Week High | 4.55 |
| 52 Week Low | 1.22 |
| PE | N/A |
| PE (group average) | N/A |
| EPS Year | -0.58 |
| EPS change Q/Q | 0% |
| EPS change Q/Q Yr ago | -20% |
| EPS change Q/Q next Q est | -20% |
| EPS change Y/Y | -40.38% |
| REV change Q/Q | 100% |
| REV change Q/Q Yr ago | -100% |
| EPS next Q est | -0.20 |
| EPS next Y est | -0.95 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |